Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Envveno Medical Corp
(NQ:
NVNO
)
3.330
+0.050 (+1.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Envveno Medical Corp
< Previous
1
2
Next >
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
November 17, 2022
Via
ACCESSWIRE
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
November 07, 2022
Via
ACCESSWIRE
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022
Via
ACCESSWIRE
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022
Via
ACCESSWIRE
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
September 19, 2022
Via
ACCESSWIRE
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 03, 2022
Via
ACCESSWIRE
enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022
Via
ACCESSWIRE
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
August 16, 2022
Via
ACCESSWIRE
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
July 08, 2022
IRVINE, CA / ACCESSWIRE / July 8, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 02, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical Announces New U.S. VenoValve(R) Patent
April 11, 2022
- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of...
From
enVVeno Medical Corporation
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
March 28, 2022
- Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data - Nine (9) VenoValve Surgeries Successfully Completed and...
From
enVVeno Medical Corporation
Via
AccessWire
One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
March 09, 2022
- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being...
From
enVVeno Medical Corporation
Via
AccessWire
Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
February 25, 2022
- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery - No venous ulcer recurrences, relapses of CVI, or safety issues - Improvements in average...
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical Announces ISO 13485 Certification
February 16, 2022
- Achievement of Quality Management System certification represents an important step towards commercialization IRVINE, CA / ACCESSWIRE / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO)...
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022
Live video webcast presentation on Tuesday, January 25th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company...
From
enVVeno Medical Corporation
Via
AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...
From
JTC Team, LLC
Via
AccessWire
enVVeno Medical to Present at the Virtual Investor Roundtable Event
November 16, 2021
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ET IRVINE, CA /...
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021
- Quarter marked by corporate rebranding and strategic prioritization of development programs - Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential...
From
enVVeno Medical Corporation
Via
AccessWire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
November 04, 2021
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating...
From
JTC Team, LLC
Via
AccessWire
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
October 22, 2021
- 75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI) - Severe CVI Impacts Approximately 2.4...
From
enVVeno Medical Corporation
Via
AccessWire
enVVeno Medical Corporation Successfully Completes Rebranding
October 01, 2021
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of...
From
enVVeno Medical Corporation
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.